Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Bullboard Posts
Comment by threefiftynineon Jun 03, 2020 3:17pm
80 Views
Post# 31108216

RE:RE:RE:Do The Right Thing

RE:RE:RE:Do The Right Thing
This stock now trades at basically 50% of the share price after the TEL AVIV SEROUSKY MEDICAL CENTRE news on May 5th. Obviously manipulated down to the pp valuation at .085. I am waiting with bated breath to see who takes this offering as it will open a can of worms if indeed they do have something on the table be it funding or phase1 and if they have nothing on the table then why not get by with the 1.4 million in the coffers---Back in December and early January they had $83k in the bank. So im pretty sure 1.4 mill is like a huge windfall. Ill hazard a guess and say it will all come out in the wash between now and june 25th. Who buys into this pp is prime going forward
Bullboard Posts